Overview
The GI-MAP uses quantitative polymerase chain reaction (qPCR) technology to assess the microbial composition of the gastrointestinal tract. It detects microorganisms that may disturb normal microbial balance or contribute to illness, and includes markers for digestion, absorption, inflammation, and immune function.
When to Order
- Chronic digestive complaints (bloating, diarrhea, constipation, abdominal pain) unresponsive to initial workup
- Suspected GI infections (food-borne, parasitic)
- Chronic conditions: diabetes, obesity, autoimmune disorders
- IBS/IBD differential diagnosis
- Brain fog, acne, psoriasis, mood disorders
- Weight loss resistance
- Post-treatment follow-up to assess intervention effectiveness
- Most commonly ordered for: Women aged 30-50 (80% female, 45% age 30-50)
Complete Biomarker List
Bacterial Pathogens
| Marker | Clinical Significance |
|---|
| Campylobacter | Acute gastroenteritis, diarrhea |
| C. difficile Toxin A | Antibiotic-associated colitis |
| C. difficile Toxin B | Antibiotic-associated colitis (more virulent) |
| Enterohemorrhagic E. coli | Hemorrhagic colitis, HUS |
| E. coli O157 | Bloody diarrhea, kidney complications |
| Enteroinvasive E. coli/Shigella | Dysentery-like illness |
| Enterotoxigenic E. coli LT/ST | Traveler's diarrhea |
| Shiga-like Toxin E. coli stx1 | Toxin-producing E. coli |
| Shiga-like Toxin E. coli stx2 | More severe toxin variant |
| Salmonella | Salmonellosis |
| Vibrio cholerae | Cholera |
| Yersinia enterocolitica | Yersiniosis, mimics appendicitis |
Parasitic Pathogens
| Marker | Clinical Significance |
|---|
| Cryptosporidium | Waterborne illness, chronic diarrhea |
| Entamoeba histolytica | Amebic dysentery |
| Giardia | Giardiasis, malabsorption |
Viral Pathogens
| Marker | Clinical Significance |
|---|
| Adenovirus 40/41 | Viral gastroenteritis |
| Norovirus GI | Acute gastroenteritis |
| Norovirus GII | Most common norovirus strain |
H. pylori Section
| Marker | Clinical Significance |
|---|
| H. pylori | Gastric/duodenal ulcers, gastritis |
| H. pylori Virulence Factor babA | Blood group antigen binding — adhesion |
| H. pylori Virulence Factor cabA | Cag pathogenicity island associated |
| H. pylori Virulence Factor cabPAI | Most virulent strain marker |
| H. pylori Virulence Factor dupA | Duodenal ulcer promoting |
| H. pylori Virulence Factor iceA | Induced by contact with epithelium |
| H. pylori Virulence Factor opiA | Outer inflammatory protein |
| H. pylori Virulence Factor vacA | Vacuolating cytotoxin — tissue damage |
Clinical Pearl: The presence of multiple virulence factors indicates a more aggressive H. pylori strain requiring more aggressive treatment. The cabPAI factor is particularly associated with gastric cancer risk.
Beneficial/Commensal Bacteria
| Marker | Functional Role |
|---|
| Akkermansia muciniphila | Mucin degradation, gut barrier integrity, metabolic health |
| Bacteroides fragilis | Immune regulation, SCFA production |
| Bifidobacterium spp. | Immune support, pathogen resistance, vitamin synthesis |
| Clostridia (class) | Mixed — includes beneficial SCFA producers |
| Enterobacter spp. | Normal flora in small amounts |
| Enterococcus spp. | Normal flora, immune modulation |
| Escherichia spp. | Normal flora, vitamin K production |
| Faecalibacterium prausnitzii | Anti-inflammatory, butyrate producer — LOW levels linked to IBD |
| Lactobacillus spp. | Immune support, pathogen resistance, lactic acid production |
Clinical Pearl: Low Akkermansia and Faecalibacterium prausnitzii together strongly suggest compromised gut barrier function and chronic inflammation. Consider polyphenol-rich foods (pomegranate, cranberry) to support Akkermansia growth.
Bacterial Phyla Ratio
| Marker | Interpretation |
|---|
| Bacteroidetes | Should be dominant phylum |
| Firmicutes | Normal secondary phylum |
| Firmicutes/Bacteroidetes Ratio | Elevated ratio associated with obesity, metabolic syndrome, inflammation |
Functional Range: Firmicutes/Bacteroidetes ratio ideally near 1:1; ratios >2:1 suggest dysbiosis pattern associated with metabolic dysfunction.
Opportunistic Bacteria
| Marker | Clinical Significance |
|---|
| Enterococcus faecalis | UTIs, endocarditis when overgrown |
| Enterococcus faecium | Antibiotic-resistant infections |
| Methanobacteriaceae (family) | Methane production — associated with constipation-dominant IBS, SIBO |
| Morganella morganii | Histamine producer — linked to histamine intolerance |
| Pseudomonas spp. | Opportunistic pathogen |
| Pseudomonas aeruginosa | Resistant infections, biofilm former |
| Staphylococcus spp. | Skin/soft tissue when overgrown |
| Staphylococcus aureus | MRSA risk, toxin production |
| Streptococcus spp. | Pharyngitis, invasive disease |
| Citrobacter spp. | UTIs, diarrhea when overgrown |
| Citrobacter freundii | Nosocomial infections |
| Fusobacterium spp. | Periodontal disease, colorectal cancer association |
| Klebsiella spp. | UTIs, pneumonia |
| Klebsiella pneumoniae | Ankylosing spondylitis association, HLA-B27 cross-reactivity |
| Mycobacterium avium | Immunocompromised patients |
| Prevotella copri | Rheumatoid arthritis association, inflammatory |
| Proteus spp. | UTIs, kidney stones |
| Proteus mirabilis | Struvite stones, UTIs |
Clinical Pearl: Elevated Klebsiella pneumoniae should prompt assessment for ankylosing spondylitis, especially in HLA-B27 positive patients. Elevated Morganella morganii is a histamine-producing organism — cross-reference with skin symptoms, migraines, anxiety.
Fungi/Yeast
| Marker | Clinical Significance |
|---|
| Candida albicans | Most common pathogenic yeast |
| Candida spp. | Other Candida species |
| Geotricum spp. | Opportunistic in immunocompromised |
| Microsporidia spp. | Intracellular parasites, immunocompromised |
| Rhodoturula spp. | Rare fungal infections |
Additional Viruses
| Marker | Clinical Significance |
|---|
| CMV (Cytomegalovirus) | Reactivation in immunocompromised |
| EBV (Epstein-Barr Virus) | Chronic fatigue association |
Non-Pathogenic Parasites / Protozoa
| Marker | Notes |
|---|
| Blastocystis hominis | Debated pathogenicity — may cause symptoms in some |
| Chilomastix mesnelli | Non-pathogenic, fecal-oral transmission indicator |
| Cyclospora cayetanenensis | Waterborne, prolonged diarrhea |
| Dientamoeba fragilis | Debated — may cause IBS-like symptoms |
| Endolimax nana | Non-pathogenic, exposure indicator |
| Entamoeba coli | Non-pathogenic, exposure indicator |
| Pentatrichomonas hominis | Non-pathogenic typically |
Worms/Helminths
| Marker | Clinical Significance |
|---|
| Ancylostoma duodenale | Hookworm — iron deficiency anemia |
| Ascaris lumbricoides | Roundworm — intestinal obstruction, malnutrition |
| Necator americanus | Hookworm — chronic blood loss |
| Trichuris trichiura | Whipworm — rectal prolapse in severe cases |
| Taenia solium/saginata | Tapeworm — cysticercosis (T. solium) |
Intestinal Health Markers
| Marker | What It Measures | Clinical Significance |
|---|
| Elastase-1 | Pancreatic exocrine function | LOW: pancreatic insufficiency, maldigestion. <200 μg/g = insufficient. Functional optimal >500 μg/g |
| Steatocrit | Fecal fat content | HIGH: fat malabsorption, bile insufficiency, pancreatic insufficiency |
| Secretory IgA (SIgA) | Mucosal immune function | LOW: mucosal immune deficiency, chronic infections. HIGH: acute immune activation, infection |
| Anti-gliadin SIgA | Gluten immune reactivity | HIGH: gluten sensitivity, celiac screening |
| Calprotectin | GI tract inflammation | "Gold standard" for GI inflammation. HIGH: IBD (Crohn's, UC). Used to distinguish IBD from IBS. >120 μg/g suggests IBD. Functional optimal <50 μg/g |
| β-Glucuronidase | Estrogen/toxin recirculation | HIGH: estrogen recirculation, impaired phase III detox, increased cancer risk. Cross-reference with DUTCH estrogen metabolites |
| Occult Blood (FIT) | GI bleeding | Positive: hemorrhoids, polyps, IBD, malignancy screening |
Antibiotic Resistance Genes
- Amoxicillin resistance
- Clarithromycin resistance
- Fluoroquinolone resistance
- Tetracycline resistance
- β-lactamase
- Macrolide resistance
- Vancomycin resistance
Clinical Pearl: Antibiotic resistance gene detection helps guide antimicrobial selection for identified pathogens. If H. pylori + clarithromycin resistance detected, avoid clarithromycin-based triple therapy.
Pattern Recognition & Cross-References
Dysbiosis Patterns
- Insufficiency Dysbiosis: Low beneficial bacteria (Lacto, Bifido, F. prausnitzii, Akkermansia) → Consider prebiotic/probiotic support, dietary fiber
- Inflammatory Dysbiosis: High opportunistic bacteria + high calprotectin + high SIgA → Active inflammation, consider anti-inflammatory protocols
- Digestive Insufficiency: Low elastase + high steatocrit → Pancreatic enzyme supplementation, bile support
- Immune Suppression: Low SIgA + recurrent infections → Mucosal immune support (SIgA-boosting nutrients: vitamin A, zinc, colostrum)
- Estrogen Recirculation: High β-glucuronidase → Impaired estrogen clearance, cross-reference with DUTCH test estrogen metabolites
Cross-References to Standard Blood Labs
- High calprotectin → Order CBC (anemia), CRP, ESR, ferritin
- High anti-gliadin SIgA → Order tissue transglutaminase (tTG-IgA), total IgA, genetic testing for HLA-DQ2/DQ8
- Low elastase → Order lipase, amylase, fat-soluble vitamins (A, D, E, K)
- H. pylori positive → Order iron studies, B12, gastrin levels
- High β-glucuronidase → Order DUTCH test for estrogen metabolites
Gut-Skin Axis (from Rupa University class)
- Intestinal permeability + microbial imbalance → skin inflammation (acne, eczema, rosacea)
- Low stomach acid → nutrient deficiencies affecting skin
- Histamine-producing organisms (Morganella, Klebsiella) → histamine-driven skin reactivity
- GI-MAP findings that correlate with skin: elevated opportunistic bacteria, low beneficial flora, high calprotectin
Gut-Brain Connection
- Dysbiosis patterns correlate with anxiety, depression, brain fog
- Low F. prausnitzii and Lactobacillus linked to mood disorders
- High Clostridia class (especially C. difficile) linked to neuropsychiatric symptoms
- Cross-reference with OAT neurotransmitter metabolites
Clinical Pitfalls
- Don't treat every finding: Some organisms (Blastocystis, Dientamoeba) are debated — correlate with symptoms
- Retest timing: Wait 6-8 weeks post-treatment before retesting
- PPIs alter results: Proton pump inhibitors change gut microbiota composition — note medication use
- Single sample limitation: qPCR is highly sensitive but represents a single time point
- β-glucuronidase context: Moderately elevated may be dietary (high animal protein) rather than pathological
- Calprotectin false positives: NSAIDs, aspirin, and infections can elevate calprotectin — doesn't always mean IBD